Funding for this research was provided by:
NIH (K23DK129784)
NIH (R01AI139126)
NIH (R01ES031940)
NIH (R01ES031940)
Article History
Accepted: 22 September 2022
First Online: 3 October 2022
Compliance with Ethical Standards
:
: Joy W. Cheng reports personal fees from Sanofi-Regeneron, Takeda, Lucid Diagnostics, outside the submitted work. Evan S. Dellon reports grants from Adare/Ellodi, Allakos, Arena, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Shire/Takeda, personal fees from Abbott, Abbvie, Adare/ Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Arena, Aslan, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, Eupraxia, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Landos, LucidDx, Morphic, Nextstone Immunology, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE, Upstream Bio, other from Allakos, Banner, Holoclara, outside the submitted work. Elizabeth T. Jensen declares no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.